Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

European Parliament greenlights Horizon Europe priorities

With a broad majority (590 yes to 42 no with 25 abstentions, the European Parliament voted  to implement the EU's innovation programme Horizon...

uniQure Receives FDA Fast Track Designation for AMT-130

AMT-130 gene therapy consistes of a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down...

Dutch-Italian team improves retinal gene therapy

Retinal gene therapy with adeno-associated viral (AAV) vectors holds promises for treating inherited and noninherited diseases of the eye. Though...

Researchers report how body fat affects imune cells

While the initial discovery of the presence of immune cells in fat was a surprising revelation to the field of immunology, it is now well-known that...

ADC Therapeutics raise $76m in Series E expansion

According to Chris Martin, PhD, Chief Executive Officer of ADC Therapeutics the proceeds will be used to fund preparations for a Biologic License...

Selvita to spin out cancer business

"There are clear opportunities for value creation from two entities with freedom to operate independently, built from the separate business...

EMA recommends nine drugs for market approval

Two orphan medicines received a positive opinion from the CHMP. Novo Nordisk's recombinant Factor VIII replacement therapy...